Oncology

CDK4

CHEMBL331

ACCUMULATING

Selectivity-first goal: CDK4/CDK6 selectivity. NOTE: current published counts derive from a CDK5-contaminated seed and are being regenerated on the corrected CDK4 seed (CHEMBL331).

데이터 무결성 / Data-lineage: Seed contamination found and corrected: the earlier CDK4 seed was CHEMBL4036 (= CDK5). The seed has been rebuilt on real CDK4 (CHEMBL331), but the currently published CDK4 library and statistics below were generated from the CDK5-derived seed and are being regenerated. Do not treat the current CDK4 numbers as validated CDK4 quality until regeneration completes.

ADMET Passed

16,735

Pareto Rank-1 Count

812

CRO

Awaiting CRO decision

Stage

Accumulating

Pareto Rank-1 is a front-membership count, not a quality ranking — the front is near-saturated, so it does not discriminate quality. Meaningful selection uses consensus + wet-lab.

Mechanism

Target: selective CDK4 inhibition — avoid CDK6-driven neutropenia observed with palbociclib. (Current library pending regeneration on the corrected CDK4 seed.)

Precedent

Palbociclib (Pfizer), Ribociclib (Novartis), Abemaciclib (Lilly) — all pan-CDK4/6.

Indications

HR+/HER2- breast cancer · Melanoma

Milestones

2026-W11

16,735 candidates accumulated (from CDK5-derived seed — being regenerated)

2026-W14

Top-10 selected for ABFE physics validation

2026-W16

CRO submission decision expected

Dashboard →Browse compounds →Methodology →